|
1
|
Hansson LE, Sparén P and Nyrén O: Survival
in stomach cancer is improving: Results of a nationwide
population-based Swedish study. Ann Surg. 230:162–169. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sun X, Mu R, Zhou Y, Dai X, Qiao Y, Zhang
S, Huangfu X, Sun J, Li L and Lu F: (1990–1992) mortality of
stomach cancer in China). Zhonghua Zhongliu Zazhi. 24:4–8. 2002.In
Chinese.
|
|
3
|
Werner M, Becker KF, Keller G and Höfler
H: Gastric adenocarcinoma: Pathomorphology and molecular pathology.
J Cancer Res Clin Oncol. 127:207–216. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Becker KF, Keller G and Hoefler H: The use
of molecular biology in diagnosis and prognosis of gastric cancer.
Surg Oncol. 9:5–11. 2000. View Article : Google Scholar
|
|
5
|
Wong SS, Kim KM, Ting JC, Yu K, Fu J, Liu
S, Cristescu R, Nebozhyn M, Gong L, Yue YG, et al: Genomic
landscape and genetic heterogeneity in gastric adenocarcinoma
revealed by whole-genome sequencing. Nat Commun. 5:54772014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kang G, Hwang WC, Do IG, Wang K, Kang SY,
Lee J, Park SH, Park JO, Kang WK, Jang J, et al: Exome sequencing
identifies early gastric carcinoma as an early stage of advanced
gastric cancer. PLoS One. 8:e827702013. View Article : Google Scholar :
|
|
7
|
Hu B, El Hajj N, Sittler S, Lammert N,
Barnes R and Meloni-Ehrig A: Gastric cancer: Classification,
histology and application of molecular pathology. J Gastrointest
Oncol. 3:251–261. 2012.PubMed/NCBI
|
|
8
|
Zang ZJ, Cutcutache I, Poon SL, Zhang SL,
McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, et al:
Exome sequencing of gastric adenocarcinoma identifies recurrent
somatic mutations in cell adhesion and chromatin remodeling genes.
Nat Genet. 44:570–574. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cancer Genome Atlas Research Network:
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ding Y, Yang Q, Wang B, Ye G and Tong X:
The correlation of MGMT promoter methylation and
clinicopathological features in gastric cancer: A systematic review
and meta-analysis. PLoS One. 11:e01655092016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baroudi O and Benammar-Elgaaied A:
Involvement of genetic factors and lifestyle on the occurrence of
colorectal and gastric cancer. Crit Rev Oncol Hematol. 107:72–81.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou J, Shen J, Seifer BJ, Jiang S, Wang
J, Xiong H, Xie L, Wang L and Sui X: Approaches and genetic
determinants in predicting response to neoadjuvant chemotherapy in
locally advanced gastric cancer. Oncotarget. 8:30477–30494.
2017.
|
|
13
|
Qi J, Zhang P, Wang Y, Chen H and Li Y:
Does total gastrectomy provide better outcomes than distal subtotal
gastrectomy for distal gastric cancer? A systematic review and
meta-analysis. PLoS One. 11:e01651792016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rabbitts TH: LMO T-cell translocation
oncogenes typify genes activated by chromosomal translocations that
alter transcription and developmental processes. Genes Dev.
12:2651–2657. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sum EY, Segara D, Duscio B, Bath ML, Field
AS, Sutherland RL, Lindeman GJ and Visvader JE: Overexpression of
LMO4 induces mammary hyperplasia, promotes cell invasion, and is a
predictor of poor outcome in breast cancer. Proc Natl Acad Sci USA.
102:7659–7664. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Visvader JE, Venter D, Hahm K, Santamaria
M, Sum EY, O'Reilly L, White D, Williams R, Armes J and Lindeman
GJ: The LIM domain gene LMO4 inhibits differentiation of mammary
epithelial cells in vitro and is overexpressed in breast cancer.
Proc Natl Acad Sci USA. 98:14452–14457. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aoyama M, Ozaki T, Inuzuka H, Tomotsune D,
Hirato J, Okamoto Y, Tokita H, Ohira M and Nakagawara A: LMO3
interacts with neuronal transcription factor, HEN2, and acts as an
oncogene in neuroblastoma. Cancer Res. 65:4587–4597. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Isogai E, Ohira M, Ozaki T, Oba S,
Nakamura Y and Nakagawara A: Oncogenic LMO3 collaborates with HEN2
to enhance neuroblastoma cell growth through transactivation of
Mash1. PLoS One. 6:e192972011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song YF, Hong JF, Liu DL, Lin QA, Lan XP
and Lai GX: miR-630 targets LMO3 to regulate cell growth and
metastasis in lung cancer. Am J Transl Res. 7:1271–1279.
2015.PubMed/NCBI
|
|
20
|
Watanabe H, Francis JM, Woo MS, Etemad B,
Lin W, Fries DF, Peng S, Snyder EL, Tata PR, Izzo F, et al:
Integrated cistromic and expression analysis of amplified NKX2-1 in
lung adenocarcinoma identifies LMO3 as a functional transcriptional
target. Genes Dev. 27:197–210. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin HP, Jiang SS and Chuu CP: Caffeic acid
phenethyl ester causes p21C ip1 induction, Akt signaling reduction,
and growth inhibition in PC-3 human prostate cancer cells. PLoS
One. 7:e312862012. View Article : Google Scholar
|
